Volume 18, Number 12—December 2012
Online Report
Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010
Table 3
Workshop results for postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infections during a public health emergency, 2010*
| Drug | Patient characteristics | Recommended dosage/frequency |
|---|---|---|
| Trimethoprim/sulfamethoxazole | Adult, >60 kg | 160 mg/800 mg tablets: 2 tablets every 12 h |
| Adult, 40–60 kg | 80 mg/400 mg tablets: 3 tablets every 12 h | |
| Adult, <40 kg | 160 mg/800 mg tablets: 1 tablet every 12 h OR | |
| 80 mg/400 mg tablets: 2 tablets every 12 h | ||
| Child |
8 mg/40 mg/kg; maximum dose 320 mg/1,600 mg every 12 h |
|
| OR |
||
| Amoxicillin/clavulanic acid (co-amoxiclav) | ||
| Adult, >60 kg | 500 mg/125 mg tablets: 3 tablets every 8 h† | |
| Adult, <60 kg | 500 mg/125 mg tablets: 2 tablets every 8 h† | |
| Child | 20 mg/5 mg/kg every 8 h; maximum dose 1,000 mg/250 mg every 8 h |
*Duration of post-exposure prophylaxis is 21 d. If the organism is susceptible and the patient does not have a documented allergy to it, oral trimethoprim/sulfamethoxazole is the agent of first choice. If the organism is resistant to trimethoprim/sulfamethoxazole or the patient is intolerant, the second-line choice is co-amoxiclav.
†Weight-based dosage based on 20 mg/5 mg/kg/dose.


